A comprehensive view of Prescription Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Executive Perspective: AstraZeneca CEO Pascal Soriot defends recent spate of acquisitions, arguing they're vital for future growth; Soriot says the deals aim to create synergy between oncology, vaccines, and respiratory disease products
Published: April 25, 2024 by FiercePharma
Merck's newly approved PAH treatment, Winrevair, forecast to reach sales of US$3.9B by 2029; the robust start to the drug's launch signals a significant boost for the company's future revenue with cancer drug Keytruda's patent expiry looming
Published: April 25, 2024 by FiercePharma
Bristol Myers reports Q1 US revenues up 7% year-over-year to US$8.5B primarily due to Eliquis, Reblozyl and Opdualag; International revenues remain flat at US$3.4B primarily due to lower average net selling prices
Published: April 25, 2024 by Business Wire
AstraZeneca reports Q1 revenue up 17% year-over-year to US$12.7B, operating profit up 22% to US$3.1B, with oncology sales growing 23% YoY to US$5.1B, metabolic and cardiovascular drug sales increasing 20% YoY to US$3.1B; annual guidance remains unchanged
Published: April 25, 2024 by BioPharma Dive
Bristol Myers Squibb reports first quarter financial results for 2024
Published: April 25, 2024 by Bristol-Myers Squibb Co.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count